Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Emiltatug ledadotin shows promising antitumor activity in various cancers, with manageable safety, highlighting its potential ...

An expert discusses how long-term follow-up data from the COMMANDS trial demonstrated sustained superiority of luspatercept ...

An expert discusses how the EPO-PRETAR trial results showed no significant difference in transfusion dependence between early ...

Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed ...

During a live event, Tony Philip, MD, and participants discussed molecular profiling and active surveillance for desmoid ...

The FDA prioritizes TAR-200 for treating high-risk bladder cancer, showcasing promising phase 2b study results and innovative ...

The ARANOTE trial (NCT04736199) represents a significant step forward in the treatment landscape for patients with metastatic hormone-sensitive prostate cancer (mHSPC). The study aimed to explore the ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...